EMA Application withdrawn: Zactima (vandetanib) — AstraZeneca

View source ↗

Summary

The EMA withdrew the application for Zactima (vandetanib) by AstraZeneca for non-small cell lung carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung

Drugs mentioned

• Zactima (vandetanib)

Snippet

Status: Application withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: AstraZeneca. Decision date: 31/12/2009